Mirsaeed Nikzad - Department of Inorganic Chemistry, University of Mazandaran, Babolsar, Iran
Amir Reza Jalilian - Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran|Radioisotope Products and Radiation Technology Section, Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria
Simindokht Shirvani-Arani - Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
Masood Arabieh - Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran

Introduction:In this work, 153Sm-zoledronate (153Sm-ZLD) was studied using computational chemistry methods and prepared for possible use in bone pain palliation therapy. Methods: The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state using computational chemistry methods followed by 153Sm-ZLD complex production, stablity, hydroxyapatite (HA) tests and also biodictribution studies in animals were studied and used for absorbed dose determination in critical organs. Results: The Sm(ZLD)2.7H2O complex was synthesized and characterized in solid state and computational chemistry methods showed that 1:1, 1:2 and 1:3 complex formation are possible in aqueous solution. 153Sm-ZLD complex was prepared with > 99% radiochemical purity (ITLC, HPLC) and specific activity of 4.4 GBq/mmol. It was stable for 24h with > 95% binding to HA with accumulation in rat bones and kidneys. Absorbed dose showed kidney and osteogenic tissue as critical organs. Conclusion: The 153Sm-ZLD complex data were compared to 153Sm-EDTMP and 153Sm-BPAMD.

153Sm, Zoledronic acid, Biodistribution, Dosimetry, Bone pain palliation